Sedative effect of remimazolam combined with alfentanil in colonoscopic polypectomy: a prospective, randomized, controlled clinical trial

Table 2 Patient demographics

Characteristics	AP Group (n = 27)	AR1 Group (n = 28)	AR2 Group (n = 30)	AR3 Group (n = 29)
age years	56.00 ± 10.13	54.11 ± 12.08	49.70 ± 8.95	52.24 ± 9.80
male/female	17/10	20/8	23/7	19/10
BMI, kg/m²	22.28 ± 1.61	22.20 ± 1.71	22.43 ± 1.77	22.40 ± 1.67
ASA classification
I	20 (74.1%)	23 (82.1%)	24 (80.0%)	23 (79.3%)
II	7 (25.9%)	5 (17.9%)	6 (20.0%)	6 (20.7%)

Note: Data are presented as mean ± SD and number (percentage)
Abbreviations: AP Alfentanil and propofol, AR1 Alfentanil and remimazolam (0.1 mg/kg), AR2 Alfentanil and remimazolam (0.15 mg/kg), AR3 Alfentanil and remimazolam (0.2 mg/kg), ASA American Society of Anesthesiologists physiological status, BMI Body mass index

ISSN: 1471-2253